{"transactions":[{"id":730228,"issuer":{"id":4740,"kind":"organization","name":"HARROW, INC."},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"RSU","published_at":"2026-06-22T23:51:02.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":5248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Stock Units vest in equal quarterly installments over a one-year period following the date of grant, subject to the Reporting Person's continued service. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Stock Units vest in equal quarterly installments over a one-year period following the date of grant, subject to the Reporting Person's continued service. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service."}],"balance_after":5248,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5248},"source":{"system":"sec-edgar","filing":"0001493152-26-029658","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000149315226029658/ownership.xml","form_type":"4"}},{"id":771551,"issuer":{"id":4740,"kind":"organization","name":"HARROW, INC."},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-19T11:00:09.000Z","date":"2026-05-18","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":31,"value":31000.0,"ownership":{"direct":true},"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001493152-26-024341","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000149315226024341/ownership.xml","form_type":"4"}},{"id":912670,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T16:15:14.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned\nsubsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."}],"balance_after":0,"derivative":{"exercise_price":10.18,"underlying":"Common Stock","underlying_shares":7125},"source":{"system":"sec-edgar","filing":"0001225755-26-000002","document":"form4-02102026_040205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000122575526000002/form4-02102026_040205.xml","form_type":"4"}},{"id":912669,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-10T16:15:14.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned\nsubsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option."}],"balance_after":0,"derivative":{"exercise_price":12.94,"underlying":"Common Stock","underlying_shares":42750},"source":{"system":"sec-edgar","filing":"0001225755-26-000002","document":"form4-02102026_040205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000122575526000002/form4-02102026_040205.xml","form_type":"4"}},{"id":912668,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock - Restricted Stock Units","published_at":"2026-02-10T16:15:14.000Z","date":"2026-02-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10075,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned\nsubsidiary of Parent (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit (\"RSU\") award that was outstanding as of immediately prior to the Effective Time held by the Reporting Person, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001225755-26-000002","document":"form4-02102026_040205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000122575526000002/form4-02102026_040205.xml","form_type":"4"}},{"id":1102497,"issuer":{"id":4740,"kind":"organization","name":"HARROW, INC."},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"RSU","published_at":"2025-06-24T22:53:58.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":7339,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of Restricted Stock Units vests in full on the one-year anniversary following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Award of Restricted Stock Units vests in full on the one-year anniversary following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service."}],"balance_after":7339,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7339},"source":{"system":"sec-edgar","filing":"0001641172-25-016324","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000164117225016324/ownership.xml","form_type":"4"}},{"id":1112267,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T17:55:43.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":7125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date."}],"balance_after":7125,"derivative":{"exercise_price":10.18,"expiration_date":"2032-06-10","underlying":"Commont Stock","underlying_shares":7125},"source":{"system":"sec-edgar","filing":"0001029142-25-000106","document":"wk-form4_1749851737.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000106/wk-form4_1749851737.xml","form_type":"4"}},{"id":1112266,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T17:55:43.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":1439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company."}],"balance_after":10075,"source":{"system":"sec-edgar","filing":"0001029142-25-000106","document":"wk-form4_1749851737.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000106/wk-form4_1749851737.xml","form_type":"4"}},{"id":1282476,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T18:29:59.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":42750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant vests over three years with 1/3 vesting on each annual anniversary of February 3, 2025, provided that Reporting Person continues to provide services to the Company through each vesting date."}],"balance_after":42750,"derivative":{"exercise_price":12.94,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":42750},"source":{"system":"sec-edgar","filing":"0001029142-25-000013","document":"wk-form4_1738798193.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000013/wk-form4_1738798193.xml","form_type":"4"}},{"id":1282475,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-02-05T18:29:59.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":8636,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 3, 2025, provided that Reporting Person continues to provide services to the Company through each  vesting date. The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 3, 2025, provided that Reporting Person continues to provide services to the Company through each  vesting date. The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 3, 2025, provided that Reporting Person continues to provide services to the Company through each  vesting date. The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock. The RSUs vest over three years with 1/3 vesting on each annual anniversary of February 3, 2025, provided that Reporting Person continues to provide services to the Company through each  vesting date. The release of RSU shares will be mandatorily deferred until the Reporting Person no longer provides services to the Company."}],"balance_after":8636,"derivative":{"underlying":"Common Stock","underlying_shares":8636},"source":{"system":"sec-edgar","filing":"0001029142-25-000013","document":"wk-form4_1738798193.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000102914225000013/wk-form4_1738798193.xml","form_type":"4"}},{"id":1477017,"issuer":{"id":4740,"kind":"organization","name":"HARROW, INC."},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"RSU","published_at":"2024-06-17T22:00:07.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":8347,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of Restricted Stock Units vests quarterly in equal installments over a one-year period following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Award of Restricted Stock Units vests quarterly in equal installments over a one-year period following the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service."}],"balance_after":8347,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8347},"source":{"system":"sec-edgar","filing":"0001493152-24-024192","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000149315224024192/ownership.xml","form_type":"4"}},{"id":1583805,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-03-11T21:26:37.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":6.657,"underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0000950170-24-029447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000095017024029447/ownership.xml","form_type":"4"}},{"id":1583804,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-03-11T21:26:37.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2033,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":16.2,"underlying":"Common Stock","underlying_shares":2033},"source":{"system":"sec-edgar","filing":"0000950170-24-029447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000095017024029447/ownership.xml","form_type":"4"}},{"id":1583803,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-11T21:26:37.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 5,000 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the \"Common Stock Merger Consideration\")."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-029447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000095017024029447/ownership.xml","form_type":"4"}},{"id":1666382,"issuer":{"id":4740,"kind":"organization","name":"HARROW, INC."},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"RSU","published_at":"2024-01-30T21:10:40.000Z","date":"2024-01-26","kind":"grant","planned":false,"acquired":true,"shares":3119,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Restricted Stock Units were received as a compensatory award for services rendered or to be rendered."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award of Restricted Stock Units vests in full on June 21, 2024. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Award of Restricted Stock Units vests in full on June 21, 2024. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the termination of service."}],"balance_after":3119,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3119},"source":{"system":"sec-edgar","filing":"0001493152-24-004312","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000149315224004312/ownership.xml","form_type":"4"}},{"id":1728443,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-28T21:29:13.000Z","date":"2023-11-27","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon the settlement of restricted stock units (\"RSUs\"). 25% of the RSUs will vest on each May 27th and November 27th of 2024 and 2025, subject to acceleration and vesting in full upon a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan) of the Issuer, and subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-23-056799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000120919123056799/doc4.xml","form_type":"4"}},{"id":1845005,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-06-23T20:40:16.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on June 21, 2024, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":23000,"derivative":{"exercise_price":0.6657,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-23-039424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000120919123039424/doc4.xml","form_type":"4"}},{"id":2155383,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2022-09-19T20:23:28.000Z","date":"2022-09-15","kind":"grant","acquired":true,"shares":20335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in three equal annual installments measured from the date of grant, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":20335,"derivative":{"exercise_price":1.62,"expiration_date":"2032-09-14","underlying":"Common Stock","underlying_shares":20335},"source":{"system":"sec-edgar","filing":"0001209191-22-050515","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000120919122050515/doc4.xml","form_type":"4"}},{"id":2265376,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-05-19T00:21:18.000Z","date":"2022-05-18","kind":"sale","acquired":false,"shares":52015,"price":12.42,"value":646026.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple trades at prices ranging from $12.15 to $13.515. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":141571,"source":{"system":"sec-edgar","filing":"0001570562-22-000107","document":"wf-form4_165291965473241.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056222000107/wf-form4_165291965473241.xml","form_type":"4"}},{"id":2265375,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-05-19T00:21:18.000Z","date":"2022-05-17","kind":"sale","acquired":false,"shares":16189,"price":13.9202,"value":225354.1178,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were sold in multiple trades at prices ranging from $13.90 to $14.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":193586,"source":{"system":"sec-edgar","filing":"0001570562-22-000107","document":"wf-form4_165291965473241.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056222000107/wf-form4_165291965473241.xml","form_type":"4"}},{"id":2339535,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-03-11T00:23:08.000Z","date":"2022-03-08","kind":"sale","acquired":false,"shares":10192,"price":9.7254,"value":99121.2768,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple trades at prices ranging from $9.50 to $9.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":209775,"source":{"system":"sec-edgar","filing":"0001570562-22-000083","document":"wf-form4_164695816288187.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056222000083/wf-form4_164695816288187.xml","form_type":"4"}},{"id":2425027,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-27T02:03:11.000Z","date":"2022-01-24","kind":"grant","acquired":true,"shares":77640,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":77640,"derivative":{"exercise_price":5.46,"expiration_date":"2032-01-25","underlying":"Common Stock","underlying_shares":77640},"source":{"system":"sec-edgar","filing":"0001570562-22-000054","document":"wf-form4_164324897583655.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056222000054/wf-form4_164324897583655.xml","form_type":"4"}},{"id":2425026,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-01-27T02:03:11.000Z","date":"2022-01-24","kind":"grant","acquired":true,"shares":53571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":219967,"source":{"system":"sec-edgar","filing":"0001570562-22-000054","document":"wf-form4_164324897583655.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056222000054/wf-form4_164324897583655.xml","form_type":"4"}},{"id":2605196,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-12T23:05:36.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":14293,"price":11.1785,"value":159774.3005,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in the second quarter of 2020 and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple trades at prices ranging from $11.1762 to $11.3055. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":166396,"source":{"system":"sec-edgar","filing":"0001570562-21-000158","document":"wf-form4a_162880951243721.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056221000158/wf-form4a_162880951243721.xml","form_type":"4/A","original_submission_date":"2021-08-12"}},{"id":2605195,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-12T22:45:41.000Z","date":"2021-08-10","kind":"sale","acquired":true,"shares":14293,"price":11.1785,"value":159774.3005,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in the second quarter of 2020 and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple trades at prices ranging from $11.1762 to $11.3055. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":194982,"source":{"system":"sec-edgar","filing":"0001570562-21-000156","document":"wf-form4_162880831776164.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056221000156/wf-form4_162880831776164.xml","form_type":"4"}},{"id":2888374,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-02-02T00:29:49.000Z","date":"2021-01-27","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of January 27, 2021, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":180689,"source":{"system":"sec-edgar","filing":"0001570562-21-000019","document":"wf-form4_161222577187164.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056221000019/wf-form4_161222577187164.xml","form_type":"4"}},{"id":2894947,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-01-27T01:51:13.000Z","date":"2021-01-25","kind":"sale","acquired":false,"shares":2699,"price":7.46,"value":20134.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in the first quarter of 2020 and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units."}],"balance_after":90689,"source":{"system":"sec-edgar","filing":"0001570562-21-000012","document":"wf-form4_161171225932694.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056221000012/wf-form4_161171225932694.xml","form_type":"4"}},{"id":3146929,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-05-15T23:59:43.000Z","date":"2020-05-13","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% of the award on July 1, 2021, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":93388,"source":{"system":"sec-edgar","filing":"0001570562-20-000093","document":"wf-form4_158958716608299.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056220000093/wf-form4_158958716608299.xml","form_type":"4"}},{"id":3302701,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-25T02:14:45.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 23, 2020, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":45000,"derivative":{"exercise_price":10.19,"expiration_date":"2030-01-23","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001570562-20-000048","document":"wf-form4_157991846794918.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056220000048/wf-form4_157991846794918.xml","form_type":"4"}},{"id":3302700,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-01-25T02:14:45.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of January 23, 2020, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":53388,"source":{"system":"sec-edgar","filing":"0001570562-20-000048","document":"wf-form4_157991846794918.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056220000048/wf-form4_157991846794918.xml","form_type":"4"}},{"id":3506102,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2019-05-31T23:51:46.000Z","date":"2019-05-31","kind":"sale","acquired":false,"shares":2612,"price":13.5345,"value":35352.114,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold solely for the purpose of covering tax withholding obligations in connection with the vesting and settlement of certain restricted stock units held by the reporting person previously described in a Form 4 filed on May 31, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple trades at prices ranging from $13.5213 to $13.5355. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":27388,"source":{"system":"sec-edgar","filing":"0001570562-19-000092","document":"wf-form4_155934669118868.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056219000092/wf-form4_155934669118868.xml","form_type":"4"}},{"id":3686582,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-26T01:21:34.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 23, 2019, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":45000,"derivative":{"exercise_price":16.19,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001570562-19-000024","document":"wf-form4_154846567750670.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056219000024/wf-form4_154846567750670.xml","form_type":"4"}},{"id":3912191,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-31T20:15:35.000Z","date":"2018-05-29","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of May 29, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":200000,"derivative":{"exercise_price":22.44,"expiration_date":"2028-05-29","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001570562-18-000044","document":"wf-form4_152779767553759.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056218000044/wf-form4_152779767553759.xml","form_type":"4"}},{"id":3912190,"issuer":{"id":5341,"kind":"organization","name":"Evolus, Inc.","symbol":"EOLS"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-05-31T20:15:35.000Z","date":"2018-05-29","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issuable on settlement of restricted stock units (\"RSUs\") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of May 29, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001570562-18-000044","document":"wf-form4_152779767553759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1225755/000157056218000044/wf-form4_152779767553759.xml","form_type":"4"}},{"id":3918638,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Common Stock","published_at":"2018-05-24T19:24:06.000Z","date":"2018-05-22","kind":"sale","acquired":false,"shares":2874,"price":30.2451,"value":86924.4174,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Table 1, Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $30.10 to $30.50. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":65497,"source":{"system":"sec-edgar","filing":"0001479290-18-000083","document":"wf-form4_152720418514363.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000083/wf-form4_152720418514363.xml","form_type":"4"}},{"id":3983906,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2018-03-23T21:12:25.000Z","date":"2018-03-22","kind":"sale","acquired":false,"shares":3431,"price":30.8478,"value":105838.8018,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Table 1, Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $30.6501 to $31.125. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":68371,"source":{"system":"sec-edgar","filing":"0001479290-18-000058","document":"wf-form4_152185393085906.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000058/wf-form4_152185393085906.xml","form_type":"4"}},{"id":3994620,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-15T20:54:26.000Z","date":"2018-03-13","kind":"exercise","acquired":true,"shares":25867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Option became fully vested as of March 18, 2017."}],"balance_after":0,"derivative":{"exercise_price":8.7,"expiration_date":"2023-05-23","underlying":"Common Stock","underlying_shares":25867},"source":{"system":"sec-edgar","filing":"0001479290-18-000048","document":"wf-form4_152116163980599.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000048/wf-form4_152116163980599.xml","form_type":"4"}},{"id":3994619,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2018-03-15T20:54:26.000Z","date":"2018-03-15","kind":"tax_withholding","acquired":false,"shares":1152,"price":31.65,"value":36460.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2016 Restricted Stock Award (\"RSA\") for 10,000 shares.  The RSA vests in three (3) equal annual installments from March 15, 2016, subject to Mrs. Silvernail's Continuous Service (as defined in the Plan) on each vesting date."}],"balance_after":71802,"source":{"system":"sec-edgar","filing":"0001479290-18-000048","document":"wf-form4_152116163980599.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000048/wf-form4_152116163980599.xml","form_type":"4"}},{"id":3994618,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2018-03-15T20:54:26.000Z","date":"2018-03-13","kind":"sale","acquired":false,"shares":25867,"price":34.5,"value":892411.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail."}],"balance_after":72954,"source":{"system":"sec-edgar","filing":"0001479290-18-000048","document":"wf-form4_152116163980599.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000048/wf-form4_152116163980599.xml","form_type":"4"}},{"id":3994617,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2018-03-15T20:54:26.000Z","date":"2018-03-13","kind":"exercise","acquired":true,"shares":25867,"price":8.7,"value":225042.9,"ownership":{"direct":true},"balance_after":98821,"source":{"system":"sec-edgar","filing":"0001479290-18-000048","document":"wf-form4_152116163980599.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000048/wf-form4_152116163980599.xml","form_type":"4"}},{"id":4003336,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-09T20:34:44.000Z","date":"2018-03-09","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Option became fully vested as of March 18, 2017."}],"balance_after":25867,"derivative":{"exercise_price":8.7,"expiration_date":"2023-05-23","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001479290-18-000041","document":"wf-form4_152064567008550.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000041/wf-form4_152064567008550.xml","form_type":"4"}},{"id":4003335,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-09T20:34:44.000Z","date":"2018-03-07","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Option became fully vested as of March 18, 2017."}],"balance_after":35867,"derivative":{"exercise_price":8.7,"expiration_date":"2023-05-23","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001479290-18-000041","document":"wf-form4_152064567008550.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000041/wf-form4_152064567008550.xml","form_type":"4"}},{"id":4003334,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2018-03-09T20:34:44.000Z","date":"2018-03-09","kind":"sale","acquired":false,"shares":10000,"price":32.5,"value":325000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail."}],"balance_after":72954,"source":{"system":"sec-edgar","filing":"0001479290-18-000041","document":"wf-form4_152064567008550.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000041/wf-form4_152064567008550.xml","form_type":"4"}},{"id":4003333,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2018-03-09T20:34:44.000Z","date":"2018-03-09","kind":"exercise","acquired":true,"shares":10000,"price":8.7,"value":87000.0,"ownership":{"direct":true},"balance_after":82954,"source":{"system":"sec-edgar","filing":"0001479290-18-000041","document":"wf-form4_152064567008550.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000041/wf-form4_152064567008550.xml","form_type":"4"}},{"id":4003332,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2018-03-09T20:34:44.000Z","date":"2018-03-07","kind":"sale","acquired":false,"shares":10000,"price":31.5,"value":315000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Table 1, Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $31.20 to $31.85. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":72954,"source":{"system":"sec-edgar","filing":"0001479290-18-000041","document":"wf-form4_152064567008550.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000041/wf-form4_152064567008550.xml","form_type":"4"}},{"id":4003331,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2018-03-09T20:34:44.000Z","date":"2018-03-07","kind":"exercise","acquired":true,"shares":10000,"price":8.7,"value":87000.0,"ownership":{"direct":true},"balance_after":82954,"source":{"system":"sec-edgar","filing":"0001479290-18-000041","document":"wf-form4_152064567008550.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000041/wf-form4_152064567008550.xml","form_type":"4"}},{"id":4051954,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2018-02-16T19:45:35.000Z","date":"2018-02-15","kind":"tax_withholding","acquired":false,"shares":1136,"price":31.75,"value":36068.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the issuer on February 15, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2017 Restricted Stock Award (\"RSA\") for 10,000 shares.  The RSA vests in three (3) equal annual installments from February 15, 2017, subject to Mrs. Silvernail's Continuous Service (as defined in the 2014 Equity Incentive Plan) on each vesting date."}],"balance_after":72954,"source":{"system":"sec-edgar","filing":"0001479290-18-000029","document":"wf-form4_151882832124548.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000029/wf-form4_151882832124548.xml","form_type":"4"}},{"id":4068540,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-02-09T21:16:27.000Z","date":"2018-02-08","kind":"grant","acquired":true,"shares":48750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 8, 2018, subject to Mrs. Silvernail's Continuous Service (as defined in the Plan) on each vesting date."}],"balance_after":48750,"derivative":{"exercise_price":29.15,"expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":48750},"source":{"system":"sec-edgar","filing":"0001479290-18-000021","document":"wf-form4_151822897304817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000021/wf-form4_151822897304817.xml","form_type":"4"}},{"id":4068539,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2018-02-09T21:16:27.000Z","date":"2018-02-08","kind":"grant","acquired":true,"shares":8125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the Restricted Stock Award shall vest in three (3) equal annual installments beginning from March 15, 2018, subject to Mrs. Silvernail's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) on each vesting date."}],"balance_after":74090,"source":{"system":"sec-edgar","filing":"0001479290-18-000021","document":"wf-form4_151822897304817.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000021/wf-form4_151822897304817.xml","form_type":"4"}},{"id":4084801,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2018-01-30T21:06:43.000Z","date":"2018-01-28","kind":"tax_withholding","acquired":false,"shares":990,"price":33.5,"value":33165.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the issuer on January 28, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2015 Restricted Stock Award (\"RSA\") for 7,290 shares.  The RSA vests in three (3) equal annual installments from January 28, 2015, subject to Mrs. Silvernail's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan) on each vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The fair market value was determined on January 26, 2018 per the Company Policy, as this was the last trading day before the vest date."}],"balance_after":65965,"source":{"system":"sec-edgar","filing":"0001479290-18-000013","document":"wf-form4_151736438903990.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000013/wf-form4_151736438903990.xml","form_type":"4"}},{"id":4111942,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2018-01-03T20:27:22.000Z","date":"2017-12-29","kind":"other","acquired":true,"shares":443,"price":22.9925,"value":10185.6775,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by Mrs. Silvernail under the Issuer's 2014 Employee Stock Purchase Plan (the \"Plan\") on December 29, 2017 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).  Mrs. Silvernail purchased the maximum number of shares allowable under the Issuer's Plan and Internal Revenue Code Section 423(b)(8) for the period ended December 31, 2017."}],"balance_after":66955,"source":{"system":"sec-edgar","filing":"0001479290-18-000004","document":"wf-form4_151502922875617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929018000004/wf-form4_151502922875617.xml","form_type":"4"}},{"id":4120151,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Stock Option (Right to buy)","published_at":"2017-12-28T20:51:21.000Z","date":"2017-12-26","kind":"exercise","acquired":false,"shares":17506,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option became fully vested as of March 18, 2017."}],"balance_after":45867,"derivative":{"exercise_price":8.7,"expiration_date":"2023-05-23","underlying":"Common Stock","underlying_shares":17506},"source":{"system":"sec-edgar","filing":"0001479290-17-000044","document":"wf-form4_151451226701828.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929017000044/wf-form4_151451226701828.xml","form_type":"4"}},{"id":4120150,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2017-12-28T20:51:21.000Z","date":"2017-12-26","kind":"exercise","acquired":true,"shares":17506,"price":8.7,"value":152302.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Mrs. Silvernail has exercised the option on December 26, 2017 and paid the exercise price in cash."}],"balance_after":66512,"source":{"system":"sec-edgar","filing":"0001479290-17-000044","document":"wf-form4_151451226701828.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000147929017000044/wf-form4_151451226701828.xml","form_type":"4"}},{"id":4167657,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-11-09T19:46:03.000Z","date":"2017-11-07","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Option became fully vested as of March 18, 2017."}],"balance_after":63373,"derivative":{"exercise_price":8.7,"expiration_date":"2023-05-23","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-060103","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117060103/doc4.xml","form_type":"4"}},{"id":4167656,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2017-11-09T19:46:03.000Z","date":"2017-11-07","kind":"sale","acquired":false,"shares":10000,"price":26.8267,"value":268267.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.40 to $27.25. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":49006,"source":{"system":"sec-edgar","filing":"0001209191-17-060103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117060103/doc4.xml","form_type":"4"}},{"id":4167655,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2017-11-09T19:46:03.000Z","date":"2017-11-07","kind":"exercise","acquired":true,"shares":10000,"price":8.7,"value":87000.0,"ownership":{"direct":true},"balance_after":59006,"source":{"system":"sec-edgar","filing":"0001209191-17-060103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117060103/doc4.xml","form_type":"4"}},{"id":4185731,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2017-10-16T20:20:31.000Z","date":"2017-10-12","kind":"sale","acquired":false,"shares":11164,"price":26.6714,"value":297759.5096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.40 to $26.85. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":49006,"source":{"system":"sec-edgar","filing":"0001209191-17-057047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117057047/doc4.xml","form_type":"4"}},{"id":4264375,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2017-07-05T21:32:06.000Z","date":"2017-06-30","kind":"other","acquired":true,"shares":604,"price":18.3175,"value":11063.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by Mrs. Silvernail under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2017 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":60170,"source":{"system":"sec-edgar","filing":"0001209191-17-043852","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117043852/doc4.xml","form_type":"4"}},{"id":4299826,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-31T21:01:50.000Z","date":"2017-05-26","kind":"exercise","acquired":false,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option became fully vested as of March 18, 2017."}],"balance_after":73373,"derivative":{"exercise_price":8.7,"expiration_date":"2023-05-23","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-17-036620","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117036620/doc4.xml","form_type":"4"}},{"id":4299825,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2017-05-31T21:01:50.000Z","date":"2017-05-26","kind":"exercise","acquired":true,"shares":23000,"price":8.7,"value":200100.0,"ownership":{"direct":true},"balance_after":59566,"source":{"system":"sec-edgar","filing":"0001209191-17-036620","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117036620/doc4.xml","form_type":"4"}},{"id":4306484,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2017-05-24T21:14:44.000Z","date":"2017-05-22","kind":"sale","acquired":false,"shares":1793,"price":20.1964,"value":36212.1452,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to an irrevocable sell to cover election previously adopted by Mrs. Silvernail."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were disposed to satisfy tax withholding obligations that arose in connection with the vesting of 4,667 shares of restricted stock on May 19, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.20. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":36566,"source":{"system":"sec-edgar","filing":"0001209191-17-035187","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117035187/doc4.xml","form_type":"4"}},{"id":4380004,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2017-03-17T19:24:35.000Z","date":"2017-03-16","kind":"tax_withholding","acquired":false,"shares":1269,"price":19.2008,"value":24365.8152,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 1,269 shares withheld by and surrendered to the Issuer on March 16, 2017, to satisfy tax withholding obligations that arose in connection with the vesting of 3,333 shares subject to the restricted stock award."}],"balance_after":38359,"source":{"system":"sec-edgar","filing":"0001209191-17-021566","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117021566/doc4.xml","form_type":"4"}},{"id":4477176,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-01-30T21:27:19.000Z","date":"2017-01-26","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from January 26, 2017, subject to Mrs. Silvernail's Continuous Service (as defined in the Plan) on each vesting date."}],"balance_after":60000,"derivative":{"exercise_price":19.7,"expiration_date":"2027-01-25","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-17-006266","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117006266/doc4.xml","form_type":"4"}},{"id":4477175,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2017-01-30T21:27:19.000Z","date":"2017-01-28","kind":"disposition_to_issuer","acquired":false,"shares":1063,"price":20,"value":21260.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares withheld by and surrendered to the Issuer on January 28, 2017, to satisfy tax withholding obligations that arose in connection with the vesting of a 2015 Restricted Stock Award (\"RSA\") for 7,290 shares. The RSA vests in three (3) equal annual installments from January 28, 2015, subject to Mrs. Silvernail's Continuous Service (as defined in the Plan) on each vesting date."}],"balance_after":39628,"source":{"system":"sec-edgar","filing":"0001209191-17-006266","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117006266/doc4.xml","form_type":"4"}},{"id":4477174,"issuer":{"id":83521,"kind":"organization","name":"Revance Therapeutics, Inc.","symbol":"RVNC"},"owners":[{"id":36281,"kind":"person","name":"SILVERNAIL LAUREN P","position":1,"cik":"0001225755","reported_name":"SILVERNAIL LAUREN P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO, CBO & Secretary"}}],"security":"Common Stock","published_at":"2017-01-30T21:27:19.000Z","date":"2017-01-26","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the Restricted Stock Award shall vest in three (3) equal annual installments beginning from February 15, 2017, subject to Mrs. Silvernail's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the \"Plan\")) on each vesting date."}],"balance_after":40691,"source":{"system":"sec-edgar","filing":"0001209191-17-006266","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1479290/000120919117006266/doc4.xml","form_type":"4"}}]}